Evidence map›Paper›PMID 24886488›Full record

Trial reportTrials2014

Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial.

Nathan R Hill, Daniel Lasserson, Ben Thompson, Rafael Perera-Salazar, Jane Wolstenholme, Peter Bower, Thomas Blakeman, David Fitzmaurice, Paul Little, Gene Feder and 6 more

Erratum issuedOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Aldosterone in vascular and metabolic dysfunction.Current opinion in nephrology and hypertension · 2016
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Nathan R Hill
Daniel Lasserson
Ben Thompson
Rafael Perera-Salazar
Jane Wolstenholme
Peter Bower
Thomas Blakeman
David Fitzmaurice
Paul Little
Gene Feder
Nadeem Qureshi
Maarten Taal
Jonathan Townend
Charles Ferro
Richard McManus
Fd Richard HobbsNuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG, UK. richard.hobbs@phc.ox.ac.uk.
University of Oxford · GBOxford University Hospitals NHS Trust · GBUniversity of Birmingham · GBUniversity of Manchester · GBQueen Elizabeth Hospital Birmingham · GBRoyal Derby Hospital · GBUniversity of Bristol · GBUniversity of Nottingham · GBUniversity of Southampton · GB

Funding

Department of Health 12/01/52Department of Health CDF/01/017Department of Health NIHR-RP-02-12-015Department of Health PB-PG-0110-21226Department of Health PDF-2012-05-205
6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is common and increasing in prevalence. Cardiovascular disease (CVD) is a major cause of morbidity and death in CKD, though of a different phenotype to the general CVD population. Few therapies have proved effective in modifying the increased CVD risk or rate of renal decline in CKD. There are accumulating data that aldosterone receptor antagonists (ARA) may offer cardio-protection and delay renal impairment in patients with the CV phenotype in CKD. The use of ARA in CKD has therefore been increasingly advocated. However, no large study of ARA with renal or CVD outcomes is underway.

methodsThe study is a prospective randomised open blinded endpoint (PROBE) trial set in primary care where patients will mainly be identified by their GPs or from existing CKD lists. They will be invited if they have been formally diagnosed with CKD stage 3b or there is evidence of stage 3b CKD from blood results (eGFR 30-44 mL/min/1.73 m2) and fulfil the other inclusion/exclusion criteria. Patients will be randomised to either spironolactone 25 mg once daily in addition to routine care or routine care alone and followed-up for 36 months. DISCUSSION: BARACK D is a PROBE trial to determine the effect of ARA on mortality and cardiovascular outcomes (onset or progression of CVD) in patients with stage 3b CKD.

trial registrationEudraCT: 2012-002672-13ISRTN: ISRCTN44522369.

Indexed as

Primary Health CareResearch DesignCardiovascular DiseasesClinical ProtocolsDisease ProgressionDrug Administration ScheduleFemaleHumansMaleMineralocorticoid Receptor AntagonistsProspective StudiesRenal Insufficiency, ChronicRisk FactorsSeverity of Illness IndexSpironolactoneTime FactorsMineralocorticoid Receptor AntagonistsSpironolactone

Identifiers

PMID24886488
PMCPMC4113231
OpenAlexW2143545250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.